Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.52 |
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13240711 | 1.00 | JAK1 (0.52) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL17942077 | 0.90 | EPHX2 (0.45) | JAK1JAK2TYK2JAK3KDM1A | |
| SCHEMBL17942105 | 0.90 | EPHX2 (0.45) | JAK1JAK2TYK2JAK3KDM1A | |
| SCHEMBL23108060 | 0.80 | JAK1 (0.47) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL30772750 | 0.80 | JAK1 (0.49) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL2997488 | 0.79 | HTR2B (0.46) | PBK | |
| SCHEMBL25519927 | 0.78 | JAK1 (0.48) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL28913117 | 0.78 | JAK1 (0.48) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL21789372 | 0.75 | JAK1 (0.45) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL948255 | 0.75 | GPR119 (0.53) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | JAK1 2827/4885JAK2 1989/4885TYK2 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.